TRACON Pharmaceuticals Stock News

Tracon Pharmaceuticals (NASDAQ:TCON) is scheduled to announce Q4 earnings results on Tuesday, Mar. 15, after market close.Consensus EPS estimate is -$0.36 and consensus revenue estimate…

SAN DIEGO, March 11, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will present a corporate overview at the Oppenheimer 32 nd Annual Healthcare Conference on Wednesday, March 16, 2022 at 4:00pm Eastern Time.

SAN DIEGO, March 11, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cance

SAN DIEGO, March 04, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the United States, announced today that it will report its fourth quarter and full year 2021 financial and operating results after the close of U.S. financial markets on Tuesday, March 15, 2022. In addition, management will host a conference call to provide an update on corporate activities and discuss the financial results.

SAN DIEGO, March 04, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cance

New York , Feb. 23, 2022 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video interviews on growth companies listed in the US and Canada, has covered the following companies: Globex Mining Enterprises reports completion of infill drilling on iron vanadium royalty property in Quebec click here Vejii says record revenues for January 2022 reflect organic and acquisitive growth click here Baird initiates coverage of TRACON Pharmaceuticals with ''outperform'' rating and $10 price target click here Electra Battery Materials partners with Ontario government, Glencore, and Talon Metals on battery materials park study click here Gratomic updates on drill progress at Capim Grosso project; reports visual graphite in six holes click here South Star Battery Metals wins approval from Brazilian mining authority for final exploration reports for Santa Cruz Mine click here Royal Road Minerals reveals results from six more drill holes at Guintär project in Colombia click here Silver Range Resources says mineralization at Strongbox property could be much more widespread than initially thought click here Therma Bright says it received patent for device for applying a topical treatment from USPTO click here New Pacific Metals sees broad gold mineralization and encouraging grades in new drill results from Carangas project click here Esports Entertainment unveils plans to install OMEGA at GAMMAX locations in the Netherlands click here Hawkmoon Resources …

Baird said that it has initiated coverage of TRACON Pharmaceuticals (NASDAQ:TCON) Inc with an outperform rating and a $10 price target.  “We see a high 70% probability of success for envafolimab, w

TRACON Pharmaceuticals Inc (TCON) shares closed this week 21.3% lower than it did at the end of last week. The stock is currently down 14.8% year-to-date, down 77.0% over the past 12 months, and down 95.4% over the past five years. This week, the Dow Jones Industrial Average fell 1.3%, and the S&P 500 fell 2.6%. Trading Activity Shares traded as high as $3.05 and as low as $2.21 this week.Trading volume this week was 42.1% lower than the 10-day average and 70.4% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.3. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price lags the S&P 500 Index this week, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average this week, lags it on a 1-year basis, and lags it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 291.5% The company's stock price performance over the past 12 months lags the peer average by 219.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

SAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer

TRACON Pharmaceuticals Inc (TCON) shares closed today 13.4% lower than it did at the end of yesterday. The stock is currently down 78.5% year-to-date, down 73.8% over the past 12 months, and down 94.6% over the past five years. Today, the Dow Jones Industrial Average rose 0.3%, and the S&P 500 fell 0.1%. Trading Activity Shares traded as high as $3.79 and as low as $2.41 this week.Shares closed 79.3% below its 52-week high and 15.6% above its 52-week low.Trading volume this week was 74.5% higher than the 10-day average and 209.6% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.3. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price lags the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 409.4% The company's stock price performance over the past 12 months lags the peer average by 305.2% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Clinical-stage pipeline includes envafolimab to treat soft-tissue sarcoma Awarded Orphan Drug designation for TRC102 to treat brain and spinal cord cancers Looking for partnerships to help with regul

TRACON Pharmaceuticals (NASDAQ:TCON) Inc shared positive results from the Independent Data Monitoring Committee (IDMC) review of interim safety and efficacy data from its ongoing ENVASARC pivotal tria

TRACON Pharmaceuticals Inc (TCON) shares closed today 18.0% higher than it did at the end of yesterday. The stock is currently down 68.8% year-to-date, down 58.1% over the past 12 months, and down 92.9% over the past five years. Today, the Dow Jones Industrial Average rose 0.6%, and the S&P 500 rose 0.6%. Trading Activity Shares traded as high as $3.79 and as low as $2.53 this week.Shares closed 70.1% below its 52-week high and 67.2% above its 52-week low.Trading volume this week was 51.9% lower than the 10-day average and 34.6% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.4. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 468.9% The company's stock price performance over the past 12 months lags the peer average by 260.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

TRACON Pharmaceuticals Inc (TCON) shares closed today 18.0% higher than it did at the end of yesterday. The stock is currently down 68.8% year-to-date, down 58.1% over the past 12 months, and down 92.9% over the past five years. Today, the Dow Jones Industrial Average rose 0.6%, and the S&P 500 rose 0.6%. Trading Activity Shares traded as high as $3.79 and as low as $2.53 this week.Shares closed 70.1% below its 52-week high and 67.2% above its 52-week low.Trading volume this week was 45.6% lower than the 10-day average and 32.0% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.4. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 468.9% The company's stock price performance over the past 12 months lags the peer average by 260.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

TRACON Pharmaceuticals Inc (TCON) shares closed today 18.0% higher than it did at the end of yesterday. The stock is currently down 73.6% year-to-date, down 65.5% over the past 12 months, and down 94.0% over the past five years. Today, the Dow Jones Industrial Average rose 0.6%, and the S&P 500 rose 0.6%. Trading Activity Shares traded as high as $3.79 and as low as $2.53 this week.Shares closed 70.1% below its 52-week high and 67.2% above its 52-week low.Trading volume this week was 12.1% lower than the 10-day average and 22.3% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.4. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 434.4% The company's stock price performance over the past 12 months lags the peer average by 255.9% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.